IRIS PubliCatt

Fabbiani, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.989
NA - Nord America 3.028
AS - Asia 770
AF - Africa 7
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 7.808
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.003
DE - Germania 1.190
IT - Italia 609
SE - Svezia 586
CN - Cina 472
PL - Polonia 428
FR - Francia 401
UA - Ucraina 325
IE - Irlanda 140
GB - Regno Unito 117
SG - Singapore 113
IN - India 93
FI - Finlandia 85
TR - Turchia 46
RU - Federazione Russa 44
BE - Belgio 21
CA - Canada 20
IR - Iran 18
HK - Hong Kong 11
JP - Giappone 8
EU - Europa 6
NL - Olanda 6
CZ - Repubblica Ceca 5
MX - Messico 5
BR - Brasile 4
CH - Svizzera 4
DK - Danimarca 4
AT - Austria 3
RO - Romania 3
BG - Bulgaria 2
EG - Egitto 2
ES - Italia 2
GR - Grecia 2
KR - Corea 2
NO - Norvegia 2
PH - Filippine 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AU - Australia 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
EE - Estonia 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
IS - Islanda 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
MM - Myanmar 1
NG - Nigeria 1
PE - Perù 1
PK - Pakistan 1
UG - Uganda 1
Totale 7.808
Salva come PNG Salva come JPEG
Città #
Chandler 653
Kraków 426
Ashburn 268
Jacksonville 247
San Mateo 156
Dublin 138
New York 138
Nanjing 135
Ann Arbor 122
Rome 121
Milan 102
Dearborn 85
Nürnberg 83
Singapore 78
Wilmington 76
Houston 74
Lawrence 71
Cattolica 66
Woodbridge 62
Nanchang 57
Lancaster 53
Redmond 50
Boston 48
Izmir 45
Redwood City 42
Shenyang 33
Seattle 32
Moscow 28
Boardman 26
Bremen 25
Kunming 25
Verona 24
Changsha 23
Mountain View 23
Fairfield 22
Hebei 22
Brussels 21
Norwalk 21
Falls Church 20
Los Angeles 20
Munich 19
Leawood 17
University Park 17
Beijing 16
Marseille 15
Shanghai 15
Tianjin 14
Augusta 13
Hangzhou 13
Jinan 13
Ottawa 13
Fremont 12
Pune 11
Hong Kong 10
Washington 10
Guangzhou 9
Simi Valley 9
Princeton 8
Zhengzhou 8
Cambridge 7
Changchun 7
Helsinki 7
Jiaxing 7
Busto Arsizio 6
Chicago 6
Detroit 6
Edinburgh 6
Kish 6
Andover 5
Hefei 5
Toronto 5
Bari 4
Bologna 4
Costa Mesa 4
Paris 4
Philadelphia 4
Sacramento 4
Ardabil 3
Auburn Hills 3
Brescia 3
Fuzhou 3
Gustavo Adolfo Madero 3
Indiana 3
Latina 3
Modena 3
Omsk 3
Phoenixville 3
Turin 3
Aci Catena 2
Amsterdam 2
Anzio 2
Athens 2
Barcelona 2
Berlin 2
Bra 2
Chengdu 2
Chongqing 2
Ciampino 2
Clearwater 2
Faenza 2
Totale 4.157
Salva come PNG Salva come JPEG
Nome #
IL PRIVATO SOCIALE: UN'OPPORTUNITÀ PER I PAZIENTI E PER LE STRUTTURE SANITARIE NELL'ATTUALE CONTESTO ECONOMICO 417
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 194
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 172
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 172
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 167
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 161
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 156
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 145
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 145
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 138
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 135
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 129
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 127
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 124
Variability of raltegravir plasma levels in the clinical setting 123
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 120
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 117
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 115
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 110
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 106
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 106
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 105
Initial antifungal strategy does not correlate with mortality in patients with candidemia 105
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 104
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 103
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 103
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 103
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 103
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 102
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 101
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 100
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 98
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 97
Effect of aging and human immunodeficiency virus infection on cognitive abilities 96
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 96
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 96
Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model? 96
Cognitive reserve and neuropsychological functioning in older HIV-infected people 96
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 93
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 93
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 92
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 92
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 92
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 91
Immune response to influenza A(H1N1)v in HIV-infected patients 91
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 91
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 91
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 90
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 88
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 87
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 87
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 85
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 84
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 83
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 82
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 80
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 76
Lipid-lowering effect of tenofovir in HIV-infected patients 76
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 76
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 75
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 75
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 74
Immune response to influenza A(H1N1)v in HIV-infected patients 73
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 71
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 69
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 69
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 67
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort 64
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 61
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 59
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 59
Liver fibrosis progression and clinical outcomes are intertwined: Role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCVcoinfected patients with detectable HCV-RNA A MASTER cohort study 55
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 53
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 52
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART 51
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 43
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 43
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received 36
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 33
Totale 7.885
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.977
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.977
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020683 0 0 64 33 86 103 49 44 69 61 93 81
2020/2021696 41 86 7 74 85 37 76 16 115 22 121 16
2021/2022806 77 64 25 61 47 40 21 129 29 73 121 119
2022/20231.639 237 261 132 258 136 191 29 145 186 11 39 14
2023/20241.021 41 231 30 106 45 212 68 22 30 50 116 70
2024/2025131 55 55 21 0 0 0 0 0 0 0 0 0
Totale 7.885